Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID G COTTER

Allopathic & Osteopathic Physicians Dermatology

NPI
1821482373
CMS profile
5697945
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$682,201.83

705 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 10 of 15; records 451–500 of 705 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID G COTTER

NPI 1821482373 · CMS profile ID 5697945

Allopathic & Osteopathic Physicians / Dermatology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 10 of 15; records 451–500 of 705 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821482373?year=2025&recipient=provider&page=10#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID G COTTER, NPI 1821482373, CMS profile ID 5697945. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 10 of 15; records 451–500 of 705 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821482373?year=2025&recipient=provider&page=10#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DAVID G COTTER, NPI 1821482373, CMS profile ID 5697945. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 10 of 15; records 451–500 of 705 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821482373?year=2025&recipient=provider&page=10#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DAVID G COTTER, NPI 1821482373, CMS profile ID 5697945, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 10 of 15; records 451–500 of 705 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1821482373?year=2025&recipient=provider&page=10#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

705 matching records · $682,201.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 705 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 451–500 of 705.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $333.2205/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184670889 CMS
E.R. Squibb & Sons, L.L.C. $122.3905/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184670892 CMS
E.R. Squibb & Sons, L.L.C. $745.9605/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184670896 CMS
UCB, Inc. $19.6005/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224746924 CMS
UCB, Inc. $35.0005/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224746926 CMS
UCB, Inc. $4,500.0005/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224746928 CMS
UCB, Inc. $4,500.0005/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224746930 CMS
ABBVIE INC. $1,500.0005/12/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201699017 CMS
ABBVIE INC. $302.8205/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201699019 CMS
ABBVIE INC. $24.6705/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201699021 CMS
ABBVIE INC. $26.8805/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201699023 CMS
ABBVIE INC. $57.0005/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201699025 CMS
ABBVIE INC. $260.2805/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201699027 CMS
E.R. Squibb & Sons, L.L.C. $2.6105/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184670827 CMS
Janssen Biotech, Inc. $18.8705/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175272166 CMS
ABBVIE INC. $16.9905/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201699015 CMS
Regeneron Healthcare Solutions, Inc. $431.0005/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212895703 CMS
Arcutis Biotherapeutics, Inc. $20.0105/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252337214 CMS
Arcutis Biotherapeutics, Inc. $7.0505/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252337216 CMS
Arcutis Biotherapeutics, Inc. $4.5705/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252337218 CMS
GENZYME CORPORATION $2,562.0005/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233590615 CMS
Galderma Laboratories, L.P. $39.3705/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234630779 CMS
Organon LLC $39.7105/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237780777 CMS
ABBVIE INC. $3,750.0005/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201699011 CMS
ABBVIE INC. $5,250.0005/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201699013 CMS
Regeneron Healthcare Solutions, Inc. $7.3805/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212895701 CMS
Galderma Laboratories, L.P. $33.7705/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234630777 CMS
Novartis Pharmaceuticals Corporation $106.4805/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200024368 CMS
Novartis Pharmaceuticals Corporation $60.2205/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200024370 CMS
Novartis Pharmaceuticals Corporation $9,125.0005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200024372 CMS
Novartis Pharmaceuticals Corporation $228.1005/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200024374 CMS
Novartis Pharmaceuticals Corporation $246.3905/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200024376 CMS
Novartis Pharmaceuticals Corporation $54.0005/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200024378 CMS
Novartis Pharmaceuticals Corporation $198.8605/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200024380 CMS
Novartis Pharmaceuticals Corporation $233.7705/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200179900 CMS
Novartis Pharmaceuticals Corporation $140.0005/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200024382 CMS
Novartis Pharmaceuticals Corporation $19.3105/01/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1200179898 CMS
Novartis Pharmaceuticals Corporation $600.1405/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200179902 CMS
GENZYME CORPORATION $37.2904/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233590617 CMS
Galderma Laboratories, L.P. $3,600.0004/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234630775 CMS
Lilly USA, LLC $122.5804/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186648935 CMS
Organon LLC $2,400.0004/30/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1237780799 CMS
Organon LLC $5,400.0004/30/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1237780807 CMS
PFIZER INC. $7.4804/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231585484 CMS
E.R. Squibb & Sons, L.L.C. $1.8004/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184670809 CMS
E.R. Squibb & Sons, L.L.C. $1.8004/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184670813 CMS
Regeneron Healthcare Solutions, Inc. $26.7304/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212895699 CMS
ABBVIE INC. $18.4004/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201699009 CMS
LEO Pharma Inc. $16.8504/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251999072 CMS
Galderma Laboratories, L.P. $118.2904/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234630771 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,712.95 98
PY2020 $14,838.16 171
PY2021 $45,054.59 224
PY2022 $99,436.26 301
PY2023 $171,066.70 425
PY2024 $366,330.68 534
PY2025 $682,201.83 705

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,637.36 11
PY2025 Principal investigator $115,344.93 12
PY2020 Recipient $2,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $9,798.40 12/04/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202528580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,508.44 11/25/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184264549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,342.00 11/14/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184261499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,198.00 11/14/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184261501
Principal investigator 1 ABBVIE INC. $9,701.60 11/05/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202521859
Principal investigator 1 ABBVIE INC. $13,491.35 10/09/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202514523
Principal investigator 1 Novartis Pharmaceuticals Corporation $282.89 10/08/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190310256
Principal investigator 1 ABBVIE INC. $12,654.25 09/04/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202509302
Principal investigator 1 ABBVIE INC. $13,196.85 08/06/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202503377
Recipient Regeneron Pharmaceuticals, Inc. $24.00 07/17/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116629
Recipient Regeneron Pharmaceuticals, Inc. $26.60 07/17/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116631
Recipient Regeneron Pharmaceuticals, Inc. $49.58 07/17/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116633
Principal investigator 1 ABBVIE INC. $10,620.95 07/02/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202495593
Recipient Regeneron Pharmaceuticals, Inc. $51.86 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116615
Recipient Regeneron Pharmaceuticals, Inc. $57.46 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116617
Recipient Regeneron Pharmaceuticals, Inc. $98.90 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116619
Recipient Regeneron Pharmaceuticals, Inc. $103.02 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116621
Recipient Regeneron Pharmaceuticals, Inc. $127.07 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116623
Recipient Regeneron Pharmaceuticals, Inc. $351.03 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116625
Recipient Regeneron Pharmaceuticals, Inc. $418.88 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116627
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,417.20 06/01/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190310258
Recipient Regeneron Pharmaceuticals, Inc. $328.96 05/15/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184116613
Principal investigator 1 ABBVIE INC. $8,133.00 05/07/2025 Non-covered Recipient Entity
LAS VEGAS DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202483155